Introduction
============

Midazolam is a short-acting drug in the benzodiazepine class that is used for inducing sedation and amnesia before medical procedures, or anesthesia \[[@B1],[@B2]\]. Sometimes, patients showed a paradoxical reaction such as crying, restlessness or vocalization after midazolam administration \[[@B3]\]. Kain et al. \[[@B4]\] reported that when children received midazolam as a premedication, some of them showed a paradoxical response and the degree of this response was related with the child\'s age or anxiety level. To explain this paradoxical reaction, a change in the activation of GABA receptors \[[@B5]\] or genetic variation of benzodiazepine receptors was suggested \[[@B6]\].

P-glycoprotein (permeability glycoprotein, P-pg) is a well-characterized ABC-transporter of the MDR/TAP subfamily. It is a 170 kDa trans-membrane glycoprotein encoded by the multidrug resistance 1 (MDR1 or ABCB1 gene). The function of P-pg is absorption, distribution or elimination of drugs. There are more than 28 of genetic variants of P-pg \[[@B7]\]. Polymorphism of the MDR 1 gene can cause refractoriness of anti-epileptic drugs \[[@B8]\], or resistance to steroids in early nephritic syndromes \[[@B9]\]. Based on this, a patient\'s responses to midazolam correlates with MDR 1 gene polymorphism. In this study, we administered midazolam preoperatively, observed the patient response and searched for a relationship with MDR1 gene polymorphism.

Materials and Methods
=====================

After approval by the Institutional Ethics Committee, 193 American Society of Anesthesiologists (ASA) I-II infants and children, aged from 2 to 12 years undergoing strabismus surgery, were enrolled in this study. Informed consent was obtained from the parents of all infants and children. Exclusion criteria included ASA status III-V, upper respiratory infection within 4 weeks, history of neurologic disease or history of genetic disorder.

After fasting according to age (less than 36 months: 6 hours, more than 36 months: 8 hours), the patient arrived at the operating room without premedication. Before administration of midazolam, the patient was checked for consciousness. Every patient was clear and anxiety degree was measured by modified Yale preoperative anxiety scale (mYPAS, [Table 1](#T1){ref-type="table"}) before midazolam injection. Midazolam 0.1 mg/kg was administered and then a patient was observed for five minutes An anesthesiologist, who measured anxiety degree before injecting midazolam, measured and recorded anxiety degree again with mYPAS after injecting midazolam five minutes later. Sedation or anxiety degree was always measured with parents attending. After mYPAS was measured five minutes later, a patient was transferred to the operation room immediately. Then, electrocardiography, non-invasive blood pressure, oxygen saturation, partial pressure of carbon dioxide and sevofluran concentration were monitored. Atropine 0.02 mg/kg (maximum dose 0.5 mg) were administered to every patient and then, thiopental 6 mg/kg was administered intravenously. After losing consciousness, the patients were ventilated manually with 8 vol% sevoflurane and 100% oxygen. For muscle relaxation, rocuronium 0.6 mg/kg was administered. During the induction of anesthesia, 2 ml of venous blood was collected for measuring midazolam concentration and conducting a genotype test. The blood was stored in a vacuum EDTA tube at -70℃. After appropriate muscle relaxation was established, insertion of a larynx mask or endotracheal intubation was performed. Then, anesthesia was maintained with 2-3 vol% sevoflurane in 50% oxygen and 50% nitrous oxide. After surgery, muscle relaxation was reversed and a patient was transferred to the recovery room after extubation with complete awakening.

According to a previous study, a non-responder was decided when activity was more than 3, vocalization was more than 4, emotional expressivity was more than 3 and arousal was more than 3 in mYPAS \[[@B4]\]. When even one of four items was decided as a non-responder, the patient was decided as a non-responder group in this study. After administering midazolam, a case of other responses, which were not classified in mYPAS, were also recorded.

DNA extraction
--------------

General anesthesia was maintained using a conventional method and 2 ml of venous blood was collected into a tube containing EDTA and stored at refrigeration temperatures. The sample was centrifuged for a genotype test and genomic DNA was extracted by QIAamp DNA Mini kit (Qiagen Inc., Valencia, CA) using the leukocyte layer. The blood sample was centrifuged at 2,500 rpm for 10 minutes and then the leukocyte layer was separated. In the leukocyte layer, 200 µl was collected and mixed with QIAGEN protease 20 µl and AL buffer 200 µl, after which it was shaken by vortex mixer for 15 seconds. After incubation at 56℃ for 10 minutes, the mixture was centrifuged. A total of 200 µl of 96-100% ethanol was added and the sample was vortexed again for 15 seconds, after which it was centrifuged again at 2,500 rpm for 10 minute The mixture was transferred into QIAamp Spin Column and centrifuged at 13,000 rpm for 1 minute. The DNA was then extracted according to the manufacturer\'s recommendation. The A260/A280 ratio of the DNA samples 1.7-1.9, which confirmed that they were relatively pure.

Analysis of the genotype
------------------------

The method of Lindberg et al. \[[@B10]\] was used for DNA amplification by polymerase chain reaction (PCR). Primers for amplification of the base sequences are shown in [Table 2](#T2){ref-type="table"}. The Total PCR reagent reaction volume was 25 µl, consisting of g-DNA 2 µl, Taq polymerase (Takara, Japan) 0.1 µl, dNTP 2 µl (100 uM), 10 × buffer 2.5 µl, AC D/W 17.4 µl, sense and antisense primers 0.5 µl each. PCR conditions were as follows: 94℃ and 5 minutes for pre-denaturation, followed by 30 cycles of 94℃ denaturation for 30 seconds, 56 annealing ℃ for 30 seconds and 72℃ synthesis for 1 minute, and finally 72℃ extension for 10 minutes. The genotype of MDR1 1236C \> T (assay ID: C\_\_7586662_10), ABCG2 421C \> A (assay ID: C\_\_15854163_70) and ABCC2 1249G \> A (assay ID: C\_\_22272980_20) SNPs was analyzed by established TaqMan Genotyping Assays (Applied Biosystems).

Statistical analysis
--------------------

Alleles of modified single nucleotide polymorphism (SNP) and the frequency of a genotype were evaluated by Chi-square test with deviation from Hardy-Weinberg equilibrium. Statistical meanings of linkage disequilibrium between pairs of SNPs were evaluated by the Fischer\'s exact test. The result was expressed as number or percentage (%), and SPSS program (SPSS Ver 19.0, Chicago, IL, USA) was used for all statistical analysis of the data. Logistic regression was used for correlation by each genotype in the responder and non-responder group after administering midazolam. Statistical significance was set as P \< 0.05.

Results
=======

A total of 193 patients were enrolled in this study. The average age was 7.5-years-old, the average height was 123.5 cm and the average weight was 27.6 kg ([Table 3](#T3){ref-type="table"}).

When anxiety degree was measured by mYPAS before administering midazolam, activity was more than 3 in 18 patients, vocalization was more than 4 in 21 patients, emotional expressivity was more than 3 in 35 patients and arousal was more than 3 in 15 patients. Twenty-five patients were applicable to two items or more and their average age was 6.8-years-old ([Table 4](#T4){ref-type="table"}).

After administering midazolam, a total of 39 patients showed anxiety and excitement (20.2%). Activity was more than 3 in 21 patients, vocalization was more than 4 in 13 patients, emotional expressivity was more than 3 in 16 patients and arousal was more than 3 in 17 patients. Eighteen patients were applicable to two items or more ([Table 4](#T4){ref-type="table"}).

Continuously high scores before and after administering midazolam were shown in 4 patients for activity, 4 patients for vocalization, 2 patients for emotional expressivity and in 4 patients for arousal. Among them, 5 patients were classified into the non-responder group (5, 7, 8, 9, and 12-years-old). Stable states before administering and high scores after administering midazolam were shown in 13 patients for activity, 14 patients for vocalization, 8 patients for emotional expressivity and in 10 patients for arousal.

After administrating midazolam, 43 patients showed smiling or laugh and no patient among them was classified into the non-responder group.

To measure the concentration of midazolam, blood samples were collected after inducing anesthesia. The average concentration was 83.4 ng/ml in the responder group and 81.6 ng/ml in the non-responder group. For estimation of a haplotype in three genotypes of 1236C \> T, 2677G \> T/A, 3435C \> T in MDR-1 gene, TGC, CAC, CGC, TTT were mainly generated and the frequency in each group was shown in [Table 5](#T5){ref-type="table"}.

When midazolam was administered as pre-treatment of anesthesia to children between 2 and 12 years old with strabismus surgery, a total of 39 patients (20.2%) showed anxiety and excitement without sedation. Genetic polymorphism and adverse reactions after administrating midazolam were not correlated (P = 0.98 or 0.99).

Discussion
==========

Midazolam is commonly used for premedication of anesthesia or as sedative in children. When it is used in the clinical field, an unexpected reaction can sometimes occur. According to a previous study, only 86% of children administered with midazolam before anesthesia showed appropriate sedation for mask ventilation \[[@B11]\]. In other studies, 14.1% of children, who were administered with 0.5 mg of midazolam, showed severe anxiety and excitement but the rate was 20.2% in this clinical study so it was more than previous studies \[[@B4]\]. Kain et al. applied 0.5 mg/kg of midazolam per oral but 0.1 mg/kg of midazolam was injected intravenously in this study and the standards to classify the responder and non-responder group were different so this may cause the difference in the results. In addition, Kain et al. reported that adverse reactions of midazolam increased as a patient was more emotional, more worried and younger. However, the average age of patients, who showed high scores in mYPAS before administrating midazolam, was not low and 5 of them were classified into the non-responder group after administrating midazolam in this study. The age of each patient was evenly distributed so it was different to the previous studies. The difference might be caused by the difference of the standards to classify after administering a drug and observing. In other words, a patient was classified by scores of every item after oral administration time after time in previous studies but a patient was classified into a non-responder group when he (or she) was applicable to even one item after measuring scores for each item in this study, which may lead to the difference.

Toll-Sander et al. \[[@B12]\] studied the relationship between midazolam and p-glycoprotein and reported that midazolam was very permeable in p-glycoprotein substrate. Therefore, p-glycoprotein is important to show the effect of midazolam and genetic polymorphism of p-glycoprotein was assumed to show the difference in the effect of midazolam but was not confirmed in this study. If the role of p-glycoprotein did not crucially change despite the genetic polymorphism, the difference in clinical signs after administering midazolam could not be explained. For this reason, further studies are required.

Walbergh et al. \[[@B13]\] reported that the maximum effect of midazolam was shown in 11 minutes when 0.1 mg/kg midazolam was administered through the nasal cavity and the average blood concentration was 72.2 ng/ml. In our study, the average blood concentration was 80 ng/ml. The blood was collected 6 minutes later after administering midazolam so the concentration may have been higher than in previous reports. Intravenous injection could be also a factor for the difference. However, the concentration of midazolam between the responder and nonresponder group was not different so a different reaction by the blood concentration was difficult to explain.

The most common reaction was a laugh in adverse reactions after administrating a drug and the specificity of genetic polymorphism was not found. Although the specificity was found, it was not harmful or significant clinically. Therefore, polymorphism of other genes was not needed.

In this clinical study, there were several limitations. Other genetic polymorphisms could be predicted although it was not studied in this study. A receptor of midazolam is GABAA receptor and γ2 subunit is essential for modification of binding sites. In previous studies, a sleeping effect of benzodiazepine did not change but anxiety was higher when γ2 subunit of GABAA was not present \[[@B14]\]. Therefore, genetic polymorphism of GABRG2, which encodes γ2 subunit of the GABAA receptor, should be studied. The other limitation was a standard of classification, which when changed led to a correlation between genetic polymorphism and reactions for midazolam.

To conclude, when anxiety was measured by mYAS after intravenous injection of 0.1 mg/kg midazolam, genetic polymorphism of MDR1 was not found in the non-responder group compared to the responder group. However, further studies are required to find correlations with other genetic polymorphisms.
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Values are number (% of total patients).
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